By: Tom Eremondi Read time: 3.5 minutes Admittedly old school, Gerry Ross’ approach to dealing with a local walk sponsor nurtured and enhanced the relationship to a surprising level. This story, however, dates back aboutRead more

Read time: 2 minutes We were so pleased to see one of our new Peer Support Volunteers, Gervais  Fournier, featured in this New Normal, Same Cancer news story, seen last month in the Le JournalRead more

Subscribe today! Our May newsletter is filled with lots of initiatives to create awareness for bladder cancer including blogs, podcasts, helpful facts, webinars and more. Bladder cancer is the 5th most common cancer in Canada andRead more

Uncertain times are upon us, around the world, as we globally respond to the coronavirus (COVID-19) that is affecting us all on some level. Many members of our bladder cancer community are directing questions our way aboutRead more

(The following content is sourced from various sites advising on the coronavirus. For more information, please see the end of this article for additional resources. Photo Credit: CDC) As news of the coronavirus (COVID-19) continues toRead more

In a recent press release, Janssen Pharmaceutical Companies of Johnson & Johnson have announced that they have received approval from Health Canada for BALVERSA™ (erdafitinib), the first FGFR Kinase inhibitor for the treatment of patientsRead more

What resources are available to help those with cancer weather the financial headwinds that come with the disease?

This session explains simple exercises in detail and how they can improve your strength, pelvic health, and aid in healing and recovery.

This webinar addresses relationships, intimacy, self-perception, and dating after a bladder cancer diagnosis, aiming to break the taboo. 

An in-depth overview of enfortumab vedotin plus pembrolizumab, the newly approved treatment for advanced bladder cancer.

This presentation provides an in-depth overview of non-muscle invasive bladder cancer, covering risk factors, diagnosis, and treatment options.